novo nordisk tirzepatide Lilly, MFN deals expected to 'democratize' obesity drugs Pfizer's weight loss pill, Novo
Pay in 4 interest-free payments of $5.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Pfizer's weight loss pill, Novo Nordisk's setback, and the FTC vs. drug middlemen: Pharma news roundup Novo Nordisk announced on February 23, 2026, that its next generation obesity drug CagriSema one of the company's most critical pipeline assets failed to outperform Eli Lilly's tirzepatide (Zepbound) in a Lilly goes toe to toe with Novo Nordisk on obesity pharmaphorum FDA Grants Tirzepatide a New Indication for Obesity Management Weight Loss Drugs: Novo's Ozempic Has a Mighty Rival From Lilly Novo Nordisk Stock Falls 16% After CagriSema Fails to Beat Zepbound WSJ
Store: clickpoint.com.au · Domain: clickpoint.com.au

























